-- Median duration of response (mDOR) in primary dataset not reached after follow-up of 17.6 months(1)
-- 18 percent of patients in the primary dataset experienced complete responses (CR), with the number of CRs increasing as the data matured(1)
-- Adult and pediatric patients in the integrated dataset had TRK fusion cancer across 24 unique tumor types, including common tumors like lung, thyroid, and colon, and rare tumors like salivary gland and infantile fibrosarcoma(1)
-- Larotrectinib is currently under Priority Review with the U.S. Food and Drug Administration (FDA) with Breakthrough Therapy, Rare Pediatric Disease, and Orphan Drug Designations
PR Newswire
WHIPPANY, N.J., Oct. 21, 2018
